

REMARKS

Basis for the amendment to claim 1 can be found in the present specification at, for example, page 4, lines 4-25.

The Office requires restriction of the claims to one of the following inventions:

1 to 58. Claims 1-4, 6-8, 15-17, 35 and 40, drawn to 58 distinct nucleic acid compositions, each of which is represented by SEQ ID NOs recited in claim 1, as well as vectors comprising said sequences.

59 to 108. Claims 5, 6-8, 15-17, 35 and 41, drawn to 50 distinct nucleic acid compositions, each of which is represented by SEQ ID NOs recited in claim 5, as well as expression vectors comprising said sequences.

109 to 216. Claims 9-10, 39 and 43, drawn to 108 antisense molecules (and kits containing the same), each of which is represented by SEQ ID NOs recited in claims 1 and 5.

217 to 323. Claims 11-14, drawn to 108 polypeptide molecules each of which is encoded by SEQ ID NOs recited in claims 1 and 5.

324 to 430. Claims 22 and 44, drawn to pharmaceutical compositions comprising nucleic acid molecules, each of which is represented by SEQ ID NOs recited in claims 1 and 5.

431 to 537. Claim 22, drawn to pharmaceutical compositions comprising polypeptide molecules, each of which is encoded by sequences represented by SEQ ID NOs recited in claims 1 and 5.

538 to 644. Claims 23 and 24, drawn to *Candida albican* cells comprising a mutation, each mutation in the DNA sequences represented by SEQ ID NOs recited in claims 1 and 5, as well as a method for identifying compounds affecting said cells growth and survival.

645. Claims 25, 26 and 28, drawn to a compound, further a pharmaceutical compound.

646. Claims 32 and 33, drawn to the plasmid pGALIPsiST-1.

647 to 753. Claims 34 and 39, drawn to antibody molecules (and kits containing the same) raised against proteins, each antibody molecule defined by the protein as encoded by nucleic acid sequences represented by SEQ ID NOs recited in claims 1 and 5.

754. Claims 29-31, drawn to a method for identification of DNA sequences from any cell or organism where the sequences encode proteins critical for that organism, further the organism is yeast, particularly *S. cerevisiae*, *S. pombe* or *C. albicans*.

755. Claim 38, drawn to a method for identification of the presence of *C. albicans* in a subject by examining antibody binding.

756. Claim 38, drawn to a method for identification of the presence of *C. albicans* in a subject by examining nucleic acid hybridization.

In response, Applicants elect Group I, the nucleic acid of SEQ ID NO: 1, with traverse. Applicants submit that a search and examination of the claims directed to the nucleic acid sequence of SEQ ID NO: 1 and the polypeptide of SEQ ID NO: 10 would not place an undue burden on the Office. See MPEP § 803. Applicants therefore submit that the polypeptide claim directed to SEQ ID NO: 10, i.e., claim 11, should also be examined in this application. Applicants further submit that search and examination of the nucleic acid molecules of claims 9 and 10 would not place an undue burden on the Office and should be examined in this application. Applicants reserve the right to file divisional application(s) on the non-elected claims.

Reconsideration and withdrawal of the requirement for restriction are respectfully requested.

Early consideration and prompt allowance of the pending claims are respectfully requested. Should the Office require anything further, it is invited to contact Applicants' representative at the telephone number listed below.

Respectfully submitted,

By /Laura A. Donnelly/
Laura A. Donnelly
Registration No. 38,435
Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
Telephone: 732-524-1729
Facsimile: 732-524-2808
Dated: April 8, 2005